top of page
The Professional Network for Healthcare Experts
Jazz Pharmaceuticals agrees $820 million Actio Biosciences acquisition to add precision epilepsy therapy ABS-1230
The acquisition would add a clinical-stage KCNT1 inhibitor for a rare genetic epilepsy with no FDA-approved treatments, while Actio’s remaining programmes will be transferred into a separate privately held company.
nuaxia
5 days ago3 min read
Lilly to Acquire AtaiBeckley in Up to $3.8bn Deal to Expand into Psychedelic Depression Therapies
Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders
nuaxia
Jul 163 min read
AstraZeneca Acquires Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.
nuaxia
Jul 153 min read
Insilico Medicine and China Medical System Expand AI Drug Discovery Partnership with $177m CNS Deal
The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.
nuaxia
Jul 143 min read
AstraZeneca Licences Sino Biopharmaceutical’s TQC3721 Respiratory Drug in Potential $1.9bn Deal
The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.
nuaxia
Jul 103 min read
VB Spine Expands Surgical Navigation Portfolio with Augmedics CT-Fluoro Technology Deal
The agreement adds advanced imaging capabilities to the xvision Spine System platform, supporting broader adoption of augmented reality navigation in spinal procedures.
nuaxia
Jul 92 min read
AstraZeneca Expands China Partnerships with Up to $2.1bn Respiratory Drug Deal
The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.
nuaxia
Jul 93 min read
Novartis Acquires Myricx Bio in Up to $1.5bn Deal to Strengthen ADC Pipeline
The acquisition adds a novel antibody-drug conjugate payload platform and two preclinical oncology programmes targeting hard-to-treat solid tumours.
nuaxia
Jul 73 min read
GSK’s $10.6bn Nuvalent Deal Marks a Shift Back to Late-Stage Oncology Scale Plays
GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade.
nuaxia
Jun 103 min read
Breaking the BTK Code: Roche Goes All-In on Degrader Strategy with $2.3B Nurix Deal
Roche has struck a deal worth up to $2.3bn with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader targeting B-cell malignancies, immunology, and neurology.
nuaxia
Jun 93 min read
Jardine Matheson Acquires I-MED Radiology Network in $2.4bn Healthcare Imaging Deal
The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure.
nuaxia
May 293 min read
Merck’s $6.7B Terns Deal Shows Big Pharma Is Preparing for Patent Cliffs
Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.
nuaxia
Mar 302 min read
bottom of page